

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#). Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|-------------------------------------|--|
| ☐ | ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| ☐ | ☒ A description of all covariates tested |
| ☒ | ☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. |
| ☒ | ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☐ | ☒ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☐ | ☒ Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Cube CDMS
Data analysis	SAS

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Policy information about [availability of data](#)

- All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
 - A description of any restrictions on data availability
 - For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

We have included the Data Availability statement as follows:

Data Availability:

The datasets generated and analyzed during the current study are not publicly available due to clinical data privacy restrictions and ethical considerations involving patient confidentiality. Access to these clinical data may be granted for non-commercial academic research purposes upon reasonable request and is subjected to approval by the study sponsor, Hyundai Bioscience. Requests should be directed to the corresponding authors, Prof. Jin-Ho Choy (e-mail: jhchoy@dankook.ac.kr) and Prof. Jun Yong Choi (e-mail: seran@yuhs.ac). Requests will be evaluated within two weeks, and the data will be available for one month after approval. The source code used for the data analysis and modeling in this study is publicly available at GitHub: <https://github.com/jhchoy1/CPCOV03-CODE.git>. All other data Supplementary the findings of this study, including processed results, are available in the Supplementary Information.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#) See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	Biological sex information has been provided and stored as part of this clinical study as mentioned in Table 1
Reporting on race, ethnicity, or other socially relevant groupings	Neither race nor ethnicity information were collected as a part of this clinical study
Population characteristics	Patients aged 19 or above with confirmed SARS-CoV-2 infection were recruited in the study. The demographic characteristics data are shown in the Table 1 of this manuscript.
Recruitment	Participants were recruited through IRB-approved online and offline advertisements, both within and outside of the study sites.
Ethics oversight	The Ministry of Food and Drug Safety (MFDS) of South Korea, local IRB of each of the study sites.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- ☒ Life sciences ☐ Behavioral & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

Sample size	The sample size was determined to compare and evaluate the safety and efficacy of the investigational drug and the placebo.
Data exclusions	No data were excluded
Replication	N/A
Randomization	The study was double blind randomized placebo-controlled trial
Blinding	The study was double blind randomized placebo-controlled trial

All studies must disclose on these points even when the disclosure is negative.

Behavioural & social sciences study design

Study description	
Research sample	
Sampling strategy	
Data collection	
Timing	
Data exclusions	
Non-participation	
Randomization	

All studies must disclose on these points even when the disclosure is negative.

Ecological, evolutionary & environmental sciences study design

Study description	
Research sample	
Sampling strategy	
Data collection	
Timing and spatial scale	
Data exclusions	
Reproducibility	
Randomization	
Blinding	

Did the study involve field work? ☐ Yes ☐ No

All studies must disclose on these points even when the disclosure is negative.

Field work, collection and transport

Field conditions

Location

Access & import/export

Disturbance

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. e, indicate whether each material,

Materials & experimental systems

n/a	Involvement in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☐	☒ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involvement in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

Validation

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Authentication

Mycoplasma contamination

Commonly misidentified lines
(See [ICLAC](#) register)

Palaeontology and Archaeology

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	
Wild animals	
Reporting on sex	
Field-collected samples	
Ethics oversight	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)
All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Specimen provenance	
Specimen deposition	
Dating methods	
☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.	
Ethics oversight	
Clinical trial registration	CRIS registration number was KCT0007307
Study protocol	Protocol number was DTC22-IP006.
Data collection	Data was collected between May 2022 and December 2022.
Outcomes	The outcomes are described in "results" section of this manuscript

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

No	Yes	Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:
☒	☐	Public health
☒	☐	National security
☒	☐	Crops and/or livestock
☒	☐	Ecosystems Any other
☒	☐	significant area

Experiments of concern

No	Yes	Does the work involve any of these experiments of concern:
☒	☐	Demonstrate how to render a vaccine ineffective
☒	☐	Confer resistance to therapeutically useful antibiotics or antiviral agents
☒	☐	Enhance the virulence of a pathogen or render a nonpathogen virulent
☒	☐	Increase transmissibility of a pathogen
☒	☐	Alter the host range of a pathogen
☒	☐	Enable evasion of diagnostic/detection modalities
☒	☐	Enable the weaponization of a biological agent or toxin
☒	☐	Any other potentially harmful combination of experiments and agents

Plants

Seed stocks	
Novel plant genotypes	
Authentication	

ChIP-seq

Data deposition

- ☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

Files in database submission

Genome browser session

(e.g. [UCSC](#))

Methodology

Replicates

Sequencing depth

Antibodies

Peak calling parameters

Data quality

Software

Flow Cytometry

Plots

Confirm that:

- ☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☐ All plots are contour plots with outliers or pseudocolor plots.
- ☐ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Instrument

Software

Cell population abundance

Gating strategy

- ☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Design type

Design specifications

Behavioral performance measures

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI

☐ Used

☐ Not used

Experimental design

Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis:

☐ Whole brain

☐ ROI-based

☐ Both

Statistic type for inference

(See [Eklund et al. 2016](#))

Correction

Models & analysis

n/a

☐ Involved in the study

☐

☐ Functional and/or effective connectivity

☐

☐ Graph analysis

☐

☐ Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis

This checklist template is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

